Cenicriviroc (CVC; a dual CCR2/CCR5 inhibitor) efficiently blocks CCL2 mediated monocyte recruitment and has been shown to exert anti-inflammatory and anti-fibrotic effects in various experimental liver disease models (78, 177, 178). This evidence concerns the gene CCR5 and liver disorder.